Latest

FDA’s acceptance of Affinia Therapeutics’ IND positions the company to test lower-dose, heart-targeted AAV gene therapy for BAG3 cardiomyopathy.

The SK bioscience–Gates MRI agreement highlights how scalable mAbs could broaden infant RSV prevention beyond high-income markets.

Industry experts discuss the standout packaging trends from 2025 that will influence the industry’s future.

The VESPER-3 trial results show that extended-interval GLP-1 dosing may expand obesity care by balancing sustained weight loss with reduced injection burden.

Janice MacLennan, CEO of Nmblr, notes how AI is transforming biopharma R&D and market access, forcing teams to prove value beyond science and redesign work around human strengths.

AdvanCell and 48Hour Discovery align peptide discovery with a Lead-212 infrastructure to build a durable targeted alpha therapy pipeline aimed at oncology markets.

This new licensing deal with SanegeneBio signals growing confidence in RNAi technologies.

The facility builds on Eli Lilly's $50 Billion investment strategy to strengthen the company's domestic manufacturing capabilities.

Agentic AI enables closed-loop, autonomous drug discovery workflows that accelerate biopharma R&D, improve efficiency, and reshape innovation.

The company’s major long-term capital commitment highlights how global drugmakers are anchoring future innovation, advanced modalities, and supply resilience within China’s life sciences ecosystem.

The guidance provides clarity to drug manufacturers on offering lower drug prices directly to patients, including patients on Medicare and Medicaid.

Cellares’ $257M Series D signals growing industry urgency to industrialize cell therapy manufacturing through automation and scalable production models.

Regulatory review of Eisai’s subcutaneous lecanemab highlights how delivery innovation may expand access and scalability for disease-modifying Alzheimer’s therapies.